2022
DOI: 10.1007/s40005-022-00606-7
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacokinetic modulation of substrate drugs via the inhibition of drug-metabolizing enzymes and transporters using pharmaceutical excipients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 95 publications
0
2
0
Order By: Relevance
“…Several factors might have contributed to these findings. One of the causes may be low bioavailability due to chemical degradation of phytochemicals and the intestinal/hepatic first pass [ 38 , 41 , 49 , 50 ], and plasma and liver concentrations of inhibitors may be insufficient for the IC 50 obtained in vitro CYP inhibition studies [ 51 , 52 ]. Consequently, a single oral dose of WGM did not have significant effects on the pharmacokinetics of buspirone in rats, suggesting that WGM cannot function as an inhibitor of CYP3A-mediated metabolism in vivo.…”
Section: Resultsmentioning
confidence: 99%
“…Several factors might have contributed to these findings. One of the causes may be low bioavailability due to chemical degradation of phytochemicals and the intestinal/hepatic first pass [ 38 , 41 , 49 , 50 ], and plasma and liver concentrations of inhibitors may be insufficient for the IC 50 obtained in vitro CYP inhibition studies [ 51 , 52 ]. Consequently, a single oral dose of WGM did not have significant effects on the pharmacokinetics of buspirone in rats, suggesting that WGM cannot function as an inhibitor of CYP3A-mediated metabolism in vivo.…”
Section: Resultsmentioning
confidence: 99%
“…Moreover, PLGA can be uptaken by M cells distributed in the Peyer’s patches of the small intestinal epithelium for distribution in the lymphatic circulation. This route is crucial, as it can bypass the first-pass mechanism and P-gp-mediated efflux in the intestinal epithelium [ 159 , 160 , 161 ]. Biodegradable nanoparticles containing DOX–PLGA have been developed for treating glioblastoma and breast cancer in animal models, but they have not yet undergone clinical studies [ 162 , 163 , 164 ].…”
Section: Obstacles In and Strategies For Formulating Dox To Enhance O...mentioning
confidence: 99%